Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Research Writing · Active pharmaceutical ingredient

Active Pharmaceutical Ingredients: Definition, Regulatory Boundaries and Specification

An active pharmaceutical ingredient (API) is the substance intended to furnish pharmacological activity in a finished product, a definition that is straightforward to state but difficult to apply at its boundaries. The boundaries of practical importance separate the API from the drug product, from the intermediates that precede it, and from the counter-ion and solid form that accompany it. Each of these boundaries determines what a specification must state.

Pubrica AcademyWritten by the medical writing and biostatistics teams Reviewed byPubrica biostatistics team Published9 October 2026 Last checked9 October 2026 Reading time13 minutes Sources26 peer-reviewed

In a manuscript, “the API” is usually reported as a name and a purity figure. In a specification it is an identity, an assay, a defined impurity profile, a characterised solid form and a manufacturing history, and the two are not interchangeable. A reader who cannot determine which polymorph and which salt were used, what the impurity limits were and where the material originated cannot interpret the dissolution curve or the stability data. This article sets out the definition, the boundaries that are genuinely contested, and the information that a manuscript must report.

Learning objectives

  • Apply a definition of API at its boundaries with the drug product, the intermediate and the starting material
  • Why salt, solid form and particle size are properties of the API, not details of the formulation
  • What a drug substance specification is expected to contain, and why identity and assay are its least informative elements
  • Which characterisation techniques answer which question, and where a single technique is not enough
  • How the API concept is strained by biologics and cell and gene therapies, and what replaces it
  • How to write an API description that a reader can reproduce or challenge

Common misconceptions

  • “API and drug product are loose synonyms.” They are different regulated objects with different specifications. The API is the substance; the drug product is the dosage form containing it plus its excipients and container closure system.
  • “The last intermediate is effectively the API.” It is not. Where the API begins determines which steps fall under finished-product GMP and which impurities must be controlled and reported.
  • “Same molecule, same material.” Lu and Rohani, in Current Medicinal Chemistry, review polymorphism and crystallisation of APIs as determinants of solubility, stability and bioavailability. Two batches of the same compound in different forms are not pharmaceutically equivalent materials.
  • “Purity is the quality attribute.” Assay is one line of a specification. The impurity profile, residual solvents, elemental impurities, water content, solid form and particle-size distribution carry most of the information.
  • “99.5% pure is a specification.” It is a result. A specification states a test, a method, an acceptance criterion and a reporting threshold.

Definition of an active pharmaceutical ingredient and its key terms

An active pharmaceutical ingredient is any substance, or mixture of substances, intended to be used in the manufacture of a drug product and which, when so used, becomes an active ingredient of that product — intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to affect the structure or function of the body. “Drug substance” is the equivalent term used in most regulatory and ICH documents, and the two are used interchangeably.

Two words carry the weight. Intended makes the classification depend on purpose rather than on chemistry, which is why the same compound can be an API in one product and an excipient in another — ethanol as a solvent and ethanol as an active antiseptic being the standard example. Becomes places the API at a point in a synthesis, not throughout it: material that only becomes the active ingredient after further chemical change is an intermediate, not an API.

The definition deliberately says nothing about dose, potency or form. Those belong to the product, and to how the substance is deployed across dosage forms — the subject of our companion page on applications of active pharmaceutical ingredients. The API has a specification; the product has a specification; they are different documents answering different questions, and ICH Q8(R2) describes the link between them through the quality target product profile and the critical quality attributes it implies 3.

Three contested boundaries of the definition

API against drug product. This boundary is the clearest and the one most often blurred in writing. The API is the substance; the drug product is the finished dosage form, containing the API, its excipients and its container closure system. A statement like “the drug was stable for 24 months” is ambiguous until the tested object is specified, because excipient interaction can make a stable API an unstable product — Narang and colleagues treat this as a primary determinant of solid dosage form stability, and Bharate and colleagues catalogue the interaction chemistries in the Journal of Excipients and Food Chemicals 20,23.

API against intermediate and starting material. Where the API “begins” is a declared point in the route of synthesis, and it determines which steps are performed under the GMP expectations that apply to API manufacture, which impurities must be controlled and reported, and how far back supply-chain documentation must reach. In a methods section, the useful practice is to state the route from the declared starting material onwards, or to state explicitly that the API was purchased and characterised rather than synthesised.

API against counter-ion and solid form. Formally the salt is part of the drug substance; functionally the counter-ion behaves like an excipient that cannot be changed independently, and Apte argues for treating it as a functional component in the International Journal of Pharmaceutical Excipients 21. The same applies to the solid form. Neither is a minor detail: both change dissolution, hygroscopicity and stability, and both must be stated. Awasthi and Banerjee’s work in RSC Pharmaceutics on atenolol and amlodipine besylate is a useful illustration, since the besylate counter-ion is part of why that compound formulates as it does 4.

Four regulated objects commonly referred to as “the drug”

ObjectWhat it isWhat it is specified onCommon writing error
Starting materialA declared material entering the API route of synthesisIdentity, purity, impurities relevant downstreamOmitted entirely, so the synthetic history cannot be traced
IntermediateA material that undergoes further chemical change before becoming the active ingredientIn-process controls; impurity carry-overCalled “the compound” interchangeably with the API
Active pharmaceutical ingredient (drug substance)The substance intended to furnish pharmacological activity, including its salt and solid formIdentity, assay, organic and elemental impurities, residual solvents, water, solid form, particle sizeReported as a name plus a purity percentage
Drug productThe finished dosage form: API plus excipients plus container closure systemDissolution or other performance test, content uniformity, degradation products, microbiological qualityStability claims made without saying whether substance or product was tested

Framing follows the drug substance and drug product distinction used in ICH Q8(R2) and the associated quality guidelines. The error column reflects what is most often missing from submitted manuscripts, not a published audit.

Solid form as a property of the API

Polymorphs, hydrates, solvates, co-crystals and amorphous forms of the same molecule differ in lattice energy and therefore in solubility, dissolution rate, hygroscopicity, chemical stability and mechanical behaviour 25,26. Lu and Rohani review polymorphism and crystallisation of APIs in Current Medicinal Chemistry as a determinant of solubility, stability and bioavailability; Saifee and colleagues give a compact account of the same ground in the International Journal of Health Research. For authors, the implication is that solid form is not a minor manufacturing detail but part of the identity of the material studied.

Three consequences follow for reporting. First, a dissolution or bioavailability result is uninterpretable without the form, because a metastable form can outperform the stable one until it converts 26. Second, any stability claim requires a solid-form check at the end of storage, not only an assay, because conversion can occur without loss of chemical purity. Third, process steps that involve solvent, water or mechanical energy — wet granulation, milling, spray drying — are opportunities for form change and should be reported with the form confirmed afterwards.

Particle-size distribution sits alongside form. For a poorly soluble API it is often the single attribute that most changes dissolution, and it is equally often reported as a single mean value when the distribution is what matters.

Contents of a drug substance specification

A specification is a list of tests, references to analytical procedures, and acceptance criteria. Identity and assay are necessary but carry little information; the more informative lines are those that limit what else is present in the material. In practice, the specification should account for: identity by a technique that discriminates between related structures; assay against a characterised reference standard; organic impurities, with individual, unspecified and total limits plus the reporting, identification and qualification thresholds applied; residual solvents by class; elemental impurities; water content; solid form; particle-size distribution where it is critical; and microbiological quality where the route of administration requires it.

The recurring failure in reporting is to give a result where a criterion is required. “Purity was 99.6% by HPLC” indicates what was measured on one occasion. “Assay 98.0–102.0% on the anhydrous basis by the stated gradient HPLC method; largest individual impurity not more than 0.15%; total impurities not more than 0.5%; reporting threshold 0.05%” states what the material was required to be, which is what makes the results comparable with those of other studies. The ICH guideline set is the reference frame for the impurity and residual-solvent expectations here.

Characterisation techniques and the questions each addresses

No single technique characterises an API, and the common error is reporting a method that cannot address the question asked of it. Chromatographic purity does not establish solid form; a melting endotherm does not establish identity; nuclear magnetic resonance establishes structure and says little about trace impurities at the levels that matter. The table below sets out the pairings, and the general rule is orthogonality: two techniques that could fail in the same way do not corroborate each other.

Two practical points follow. Reference standards need their own provenance — compendial, or characterised in-house with the characterisation stated — because an assay is only as good as what it is measured against. Stability-indicating capability must also be demonstrated, not asserted: a method is stability-indicating if forced-degradation samples show the degradants resolved from the parent peak, and that experiment belongs in the paper or its supplement.

Which characterisation question each technique can answer

QuestionTechniques that answer itWhat it cannot be answered by
Is it the right molecule?NMR, mass spectrometry, infrared spectroscopy, comparison with a characterised reference standardMelting point or a single chromatographic retention time
How much of it is there?Validated chromatographic assay against a characterised reference standard, on a stated basis (anhydrous, as-is)Mass balance, or purity by area percentage alone
What else is in it?Stability-indicating chromatography with forced degradation; headspace GC for residual solvents; ICP-MS for elemental impuritiesThe assay method run at analytical concentration
Which solid form is it?X-ray powder diffraction, supported by DSC and thermogravimetry; Raman or solid-state NMR for mixturesChemical purity, solubility, or appearance
How is the water bound?Karl Fischer titration plus thermogravimetry; dynamic vapour sorption for hygroscopicityLoss on drying alone, which cannot distinguish surface from lattice water
What is the particle size distribution?Laser diffraction or image analysis, reported as a distribution with the dispersion method statedA single mean or a microscope photograph

A technique-to-question mapping compiled from the solid-state and specification literature cited on this page, including Lu and Rohani in Current Medicinal Chemistry and Saifee and colleagues in the International Journal of Health Research. It is a reporting guide, not a compendial requirement list.

Proportionality of the required level of characterisation

It may reasonably be asked whether this level of specification detail is justified in a research paper. The relevant context is that development of a new active substance is extremely expensive and that most attrition is not visible. Wouters, McKee and Luyten, in JAMA, estimated the median capitalised research and development cost of bringing a new medicine to market at $1,141.7 million in 2018 dollars, with a 95% confidence interval from $888.1 million to $1,480.8 million 16. Their study also illustrates the problem of transparency: of 355 new drugs and biologics approved by the FDA between 2009 and 2018, usable research and development data could be assembled for only 63, or 18% 16.

The 18% figure is pertinent when deciding how much to report. The field’s evidence base on its own economics is thin because the underlying records were not shared in a usable form 16. The same logic applies at the scale of a single API: a result reported without form, source and specification cannot be pooled, replicated or built on, however good the experiment was.

$1,141.7Mmedian capitalised R&D cost per new medicine (95% CI $888.1M–$1,480.8M), 2018 US dollars
355new drugs and biologics approved by the FDA, 2009–2018
18%of those approvals (63 products) had usable R&D cost data

Source: Wouters OJ, McKee M, Luyten J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA. 2020;323(9):844-853.

Limits of the API concept

For small molecules the API is a well-defined chemical entity. For biologics it is a population of closely related molecules whose distribution is determined by the manufacturing process, which is why the process is treated as part of the product definition 13. Jiskoot and colleagues, in the Journal of Pharmaceutical Sciences, and Hu and colleagues, in the AAPS series, describe high-concentration monoclonal antibody formulation as a problem of aggregation, viscosity and interfacial stress rather than of assay and impurity limits — an entirely different set of critical quality attributes 13,15. Our bio-macromolecules page sets out what changes in characterisation and reporting.

For cell and gene therapies the concept strains further. The Committee for Advanced Therapies, writing in Nature Reviews Drug Discovery, set out why advanced therapy medicinal products do not fit a drug-substance-plus-drug-product framework comfortably 24. Shchaslyvyi and colleagues, in Pharmaceuticals, survey approved gene therapy products and vectors, where the active principle is a vector carrying a transgene; Alhakamy and colleagues, in Drug Discovery Today, trace the same translational path 9,14. Estapé Senti and colleagues, in Advanced Drug Delivery Reviews, describe mRNA delivery systems where the lipid nanoparticle is inseparable from the activity — so the question of what counts as the API has no clean answer, and in those fields the term is often not used 7.

Authors writing in these areas should not force the vocabulary. “Drug substance” should be used where it applies; otherwise, the active principle should be described in the terms used by the field: vector and transgene, cell product and potency assay, antibody and higher-order structure.

Reporting the API in a manuscript

The preceding sections reduce to a short list for a methods section: the identity of the substance, its salt and solid form, its source and whether the authors synthesised it, the specification it met, how compliance was verified, and how it was stored. Each item is one clause. The before-and-after below is a paragraph from a dissolution study, which is where under-specified API descriptions are most consequential, because the result depends on form and particle size more than on anything the authors chose to report.

Where a study compares formulations rather than materials, the API paragraph should still make clear that the same API lot was used throughout; otherwise, formulation and material differences are confounded and a reviewer cannot separate them. The same discipline applies on the device side; see material selection for medical devices for the parallel expectations.

An API paragraph from a dissolution study, reported two ways

Leaves the result uninterpretable

Carbamazepine (purity greater than 99%) was obtained from a commercial supplier and used as received. Dissolution was performed in USP apparatus 2 and samples were analysed by HPLC at 285 nm.

Which solid form? Carbamazepine has several, and they dissolve at different rates, so the dissolution curve cannot be interpreted.

Which hydration state? Conversion to the dihydrate during dissolution is a known behaviour of this compound and is not addressed.

What particle size? For a poorly soluble drug this often dominates the result and is not reported at all.

Purity against what? “Greater than 99%” is a result with no method, no basis and no reference standard.

One lot or several? Unstated, so a material effect cannot be separated from a formulation effect.

Was the method stability-indicating? At a single wavelength with no validation range, degradants could co-elute with the parent.

Lets the result be compared

Carbamazepine anhydrous form III (free base, no counter-ion) was purchased from a single supplier as one lot (lot CBZ-4471, stated assay 99.4% on the anhydrous basis) and used without recrystallisation. The solid form was confirmed as form III by X-ray powder diffraction against the reference pattern on receipt and again after 6 months of storage at 25 degrees C and 60% relative humidity, with no evidence of conversion to the dihydrate; water content by Karl Fischer titration was 0.3% w/w. Particle size was measured by laser diffraction after dispersion in 0.1% polysorbate 80, giving d10 4 micrometres, d50 31 micrometres and d90 96 micrometres. Dissolution was performed in USP apparatus 2 at 50 rpm in 900 mL of 1% sodium lauryl sulfate at 37 degrees C, and samples were quantified by a stability-indicating gradient HPLC method at 285 nm, validated over 1 to 100 micrograms per millilitre, against a compendial reference standard.

The form is named and confirmed by a technique that can distinguish forms, at the start and the end of storage.

Hydration state is bounded by a water determination, so the known conversion risk is addressed rather than ignored.

Particle size is given as a distribution with the dispersion method, which is what makes it comparable.

Assay is stated with its basis, and the reference standard is identified.

A single lot is declared, so formulation comparisons within the study are not confounded by material variation.

The analytical method is stated as stability-indicating and validated over a named range.

The second version is longer, but each addition is a measurement that the authors had already made or could readily have made. The gain is comparability: the first paragraph describes a result that cannot be placed against the literature, whereas the second describes a material that another laboratory could obtain.

Unresolved questions

Polymorph prediction remains incomplete. Computational crystal structure prediction has improved, but neither Lu and Rohani nor Saifee and colleagues present it as able to guarantee that the form obtained is the most stable one, and late-appearing polymorphs remain a known hazard rather than a solved problem 25,26. The practical consequence is that a form claim is always provisional; authors should report the screen performed and its conditions, not only the form obtained.

The choice of a starting point when the substance has not yet been selected is a separate question; our page on selecting materials for drug development works through it, and the concepts and definitions hub lists the related terms.

The economics are also less settled than is commonly suggested. Wouters and colleagues’ estimate rests on the 18% of approvals for which usable data existed, and they are explicit that this limits generalisation; estimates from other groups differ substantially, and the differences come from methodology — which costs are capitalised, at what rate, over what attrition assumption — rather than from new data 16. Any figure should be quoted with its source and its interval, or not at all.

Key points

Key points

An API is the substance intended to furnish pharmacological activity in a finished product — a definition that turns on intent and on the point in a synthesis at which the material becomes active. It is not the drug product, and it is not the intermediate before it. Its identity includes the salt and the solid form, because both change dissolution, stability and bioavailability. A specification is tests, methods and acceptance criteria, not a reported purity figure. For biologics, cell and gene therapies the framework strains, and the field’s own vocabulary is preferable to applying the term API to a vector or a cell population.

Application to your study

Application to your study

  1. The object of each claim should be specified. Every stability, purity or dissolution statement should make clear whether it concerns the drug substance or the drug product.
  2. The salt and the solid form should be named in the first sentence of the API description. The description should state free base or salt, the counter-ion, the polymorph or hydrate, and the technique that confirmed it.
  3. The source of the material, and whether it was synthesised by the authors, should be stated. For purchased material, the supplier and lot should be given; for synthesised material, the route from the declared starting material and the purification should be described.
  4. Every purity result should be expressed as a specification. The specification comprises the test, method, acceptance criterion, reporting threshold, and the basis on which the assay is calculated.
  5. Particle size should be reported as a distribution. Values of d10, d50 and d90 should be given with the dispersion method, not a single mean, particularly for a poorly soluble compound.
  6. Solid form should be re-examined after storage. Chemical assay will not detect a form conversion, and conversion is the more common cause of a changed dissolution profile.
  7. The assay should be demonstrated to be stability-indicating. Forced-degradation chromatograms should be provided in the supplement; assertion alone is insufficient.
  8. A single API lot should be used across a formulation comparison, and this should be reported. Otherwise material and formulation effects are confounded and the comparison cannot carry its conclusion.
  9. For biologics and advanced therapies, the term API should not be used. The active principle should be described in the terminology of the field, with specification of the attributes that control it.

Frequently asked questions

The API, or drug substance, is the substance intended to furnish pharmacological activity. The drug product is the finished dosage form containing it — API plus excipients plus container closure system. They are specified separately and on different attributes: the API on identity, assay, impurities, residual solvents, water, solid form and particle size; the product on performance tests such as dissolution, content uniformity, degradation products and microbiological quality. The distinction matters for writing because a stable API can give an unstable product through excipient interaction, which Narang and colleagues treat as a primary determinant of solid dosage form stability. Any stability claim should state which object was tested.

Formally, yes: the drug substance is the salt, so amlodipine besylate rather than amlodipine. Functionally the counter-ion behaves like an excipient that cannot be varied independently: it changes solubility, hygroscopicity, crystal habit and sometimes stability. Apte makes this argument explicitly in the International Journal of Pharmaceutical Excipients, proposing that counter-ions be treated as functional components. For reporting purposes the resolution is straightforward: the salt form should always be named, “the drug” should not denote both the free base and the salt in the same paper, and the conversion factor should be stated if doses are reported on a free-base basis.

An intermediate undergoes further chemical change before becoming the active ingredient; the API is the material that becomes the active ingredient in the product without further chemical transformation. The boundary is a declared point in the route of synthesis, and it has consequences: it determines which manufacturing steps fall under API GMP expectations, which impurities must be controlled and reported, and how far back supply-chain documentation reaches. In a manuscript, authors should state the route from the declared starting material onwards, or state explicitly that the material was purchased and characterised rather than synthesised; either is acceptable, whereas ambiguity is not.

Tests, references to the analytical procedures, and acceptance criteria — not results. The specification should account for: identity by a discriminating technique; assay against a characterised reference standard, with the basis stated; organic impurities with individual, unspecified and total limits plus the reporting, identification and qualification thresholds applied; residual solvents by class; elemental impurities; water content; solid form; particle-size distribution where it is critical to performance; and microbiological quality where the route of administration requires it. The ICH quality guidelines are the reference frame for the impurity and residual-solvent expectations. Identity and assay are necessary but carry the least information.

Because different solid forms of the same molecule have different lattice energies and therefore different solubility, dissolution rate, hygroscopicity, chemical stability and compaction behaviour. Lu and Rohani review this in Current Medicinal Chemistry as a determinant of solubility, stability and bioavailability, and Saifee and colleagues cover the same ground in the International Journal of Health Research. In practice, a dissolution result without the form stated is uninterpretable; a metastable form can outperform the stable one until it converts; wet granulation, milling and spray drying can all change form; and form prediction is not reliable enough to replace an experimental screen, so late-appearing polymorphs remain a genuine hazard.

Only loosely, and forcing the concept usually obscures more than it clarifies. A biologic active substance is a population of closely related molecules whose distribution is set by the process, so the process is part of the product definition, and the controlling attributes are aggregation, higher-order structure and post-translational heterogeneity rather than assay and impurity limits. The Committee for Advanced Therapies set out in Nature Reviews Drug Discovery why advanced therapy medicinal products fit the framework poorly; Shchaslyvyi and colleagues, in Pharmaceuticals, survey approved gene therapy products where the active principle is a vector plus transgene. The field’s own vocabulary should be used instead.

Wouters, McKee and Luyten estimated in JAMA a median capitalised research and development cost of $1,141.7 million in 2018 dollars, with a 95% confidence interval from $888.1 million to $1,480.8 million. The estimate should be interpreted with caution: of 355 new drugs and biologics approved by the FDA between 2009 and 2018, usable cost data existed for only 63, or 18%, and the authors are explicit that this limits generalisation. Published estimates from different groups differ substantially, and the differences come from methodological choices — which costs are capitalised, at what discount rate, under what attrition assumption — rather than from new data. Any figure should be quoted with its source and its interval.

Yes, wherever the material’s properties could influence the result — which for dissolution, stability, compaction and formulation comparisons is almost always. One lot used throughout a formulation comparison, stated as such, lets a reader separate a formulation effect from a material effect; several unidentified lots make that impossible. Where the authors synthesised the material, the equivalent information is the route, the purification and the characterisation data. This parallels the excipient case, where Dave and colleagues, in the Journal of Pharmaceutical Sciences, show lot-to-lot functionality differences large enough to change dosage form behaviour.

References

  1. U.S. Food and Drug Administration, CDER Office of Generic Drugs. FDA's Inactive Ingredient Database (IID) Program & AI Consideration. FDA FY2026 Generic Drug Science and Research Initiatives Public Workshop. 2026. read 9 October 2026. fda.gov
  2. U.S. Food and Drug Administration. Questions and Answers Regarding Enhancements to the Inactive Ingredient Database (IID). U.S. Food and Drug Administration (CDER). 2019. read 9 October 2026. fda.gov
  3. International Council for Harmonisation; U.S. Food and Drug Administration (CDER/CBER). Guidance for Industry Q8(R2) Pharmaceutical Development. U.S. Department of Health and Human Services, Food and Drug Administration. 2009;Revision 2. read 9 October 2026. fda.gov
  4. Awasthi G, Banerjee S. Merged in silico-in vitro validations of atenolol and amlodipine besylate with excipient interactions for the design of solid oral dosage forms. RSC Pharmaceutics. 2026. doi:10.1039/D6PM00014B read 9 October 2026. doi.org/10.1039/D6PM00014B
  5. Comoglu T, Ozyilmaz ED. Pharmaceutical excipients in pediatric and geriatric drug formulations: safety, efficacy, and regulatory perspectives. Pharmaceutical Development and Technology. 2025;30(1):1-9. doi:10.1080/10837450.2024.2441181 read 9 October 2026. doi.org/10.1080/10837450.2024.2441181
  6. Ginn SL, Mandwie M, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2023-an update. The Journal of Gene Medicine. 2024;26(8):e3721. doi:10.1002/jgm.3721 read 9 October 2026. doi.org/10.1002/jgm.3721
  7. Estape Senti M, Garcia Del Valle L, Schiffelers RM. mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond. Advanced Drug Delivery Reviews. 2024;206:1-17. doi:10.1016/j.addr.2024.115190 read 9 October 2026. doi.org/10.1016/j.addr.2024.115190
  8. Jain S, Kaur S, Rathi R, Nagaich U, Singh I. Application of co-processed excipients for developing fast disintegrating tablets: A review. Polymers in Medicine. 2023;53(1):59-68. doi:10.17219/pim/158009 read 9 October 2026. doi.org/10.17219/pim/158009
  9. Shchaslyvyi AY, Antonenko SV, Tesliuk MG, Telegeev GD. Current State of Human Gene Therapy: Approved Products and Vectors. Pharmaceuticals. 2023;16(10):1416. doi:10.3390/ph16101416 read 9 October 2026. doi.org/10.3390/ph16101416
  10. Comoglu T, Ozyilmaz ED. Pharmaceutical product development: a "quality by design" (QbD) approach. 2023;1:285-310. doi:10.1016/B978-0-323-91817-6.00001-2 read 9 October 2026. doi.org/10.1016/B978-0-323-91817-6.00001-2
  11. Liu R, Luo C, Pang Z, et al. Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment. Chinese Chemical Letters. 2022. doi:10.1016/j.cclet.2022.05.032 read 9 October 2026. doi.org/10.1016/j.cclet.2022.05.032
  12. Rouaz El Hajoui K, Chiclana Rodriguez B, Nardi Ricart A, et al. Excipients in the Paediatric Population: A Review. Pharmaceutics. 2021;13(3):387. doi:10.3390/pharmaceutics13030387 read 9 October 2026. doi.org/10.3390/pharmaceutics13030387
  13. Jiskoot W, Hawe A, Menzen T, Volkin DB, Crommelin DJA. Ongoing challenges to develop high concentration monoclonal antibody-based formulations for subcutaneous administration: Quo Vadis? Journal of Pharmaceutical Sciences. 2021;111(4):861-867. doi:10.1016/j.xphs.2021.11.008 read 9 October 2026. doi.org/10.1016/j.xphs.2021.11.008
  14. Alhakamy NA, Curiel DT, Berkland CJ. The era of gene therapy: From preclinical development to clinical application. Drug Discovery Today. 2021;26(7):1602-1619. doi:10.1016/j.drudis.2021.03.021 read 9 October 2026. doi.org/10.1016/j.drudis.2021.03.021
  15. Hu Q, Jiang B, Liu D, Tang X, Daly T, Shameem M. Chapter 14: Practical Considerations in High Concentration Formulation Development for Monoclonal Antibody Drug Products. AAPS Advances in the Pharmaceutical Sciences Series. 2020;35:343-372. doi:10.1007/978-3-030-31415-6_14 read 9 October 2026. doi.org/10.1007/978-3-030-31415-6_14
  16. Wouters OJ, McKee M, Luyten J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA. 2020;323(9):844-853. doi:10.1001/jama.2020.1166 read 9 October 2026. doi.org/10.1001/jama.2020.1166
  17. Belayneh A, Tadese E, Molla F. Safety and Biopharmaceutical Challenges of Excipients in Off-Label Pediatric Formulations. International Journal of General Medicine. 2020;13:1051-1066. doi:10.2147/IJGM.S280330 read 9 October 2026. doi.org/10.2147/IJGM.S280330
  18. Liew KB, Gaurav A, Mandal UK. A REVIEW ON CO-PROCESSED EXCIPIENTS: CURRENT AND FUTURE TREND OF EXCIPIENT TECHNOLOGY. International Journal of Pharmacy and Pharmaceutical Sciences. 2019;11(1):1-9. doi:10.22159/ijpps.2019v11i1.29265 read 9 October 2026. doi.org/10.22159/ijpps.2019v11i1.29265
  19. Milic J, Calija B, Krajisnik D. Excipients functionality: Importance and compendial status. Arhiv za farmaciju. 2016;66(2):71-90. doi:10.5937/arhfarm1602071M read 9 October 2026. doi.org/10.5937/arhfarm1602071M
  20. Bharate SS, Bharate SB, Bajaj AN. Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: a comprehensive review. Journal of Excipients and Food Chemicals. 2016;1(3). read 9 October 2026. doaj.org
  21. Apte S. The counter ion: expanding excipient functionality. International Journal of Pharmaceutical Excipients. 2016;2(2). doi:10.66617/001c.1126 read 9 October 2026. doi.org/10.66617/001c.1126
  22. Dave VS, Saoji SD, Raut NA, Haware RV. Excipient Variability and Its Impact on Dosage Form Functionality. Journal of Pharmaceutical Sciences. 2015;104(3):906-915. doi:10.1002/jps.24299 read 9 October 2026. doi.org/10.1002/jps.24299
  23. Narang AS, Desai D, Badawy S. Impact of Excipient Interactions on Solid Dosage Form Stability. Excipient Applications in Formulation Design and Drug Delivery. 2015:93-137. doi:10.1007/978-3-319-20206-8_5 read 9 October 2026. doi.org/10.1007/978-3-319-20206-8_5
  24. Committee for Advanced Therapies (CAT) and CAT Scientific Secretariat. Challenges with advanced therapy medicinal products and how to meet them. Nature Reviews Drug Discovery. 2010;9(3):195-201. doi:10.1038/nrd3052 read 9 October 2026. doi.org/10.1038/nrd3052
  25. M Saifee, N Inamda, D Dhamecha, A Rathi. Drug polymorphism: a review. International Journal of Health Research. 2010;2(4). doi:10.4314/ijhr.v2i4.55423 read 9 October 2026. doi.org/10.4314/ijhr.v2i4.55423
  26. Lu J, Rohani S. Polymorphism and Crystallization of Active Pharmaceutical Ingredients (APIs). Current Medicinal Chemistry. :884-905. doi:10.2174/092986709787549299 read 9 October 2026. doi.org/10.2174/092986709787549299

Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.

Pubrica Academy. (2026, October 9). Active Pharmaceutical Ingredients: Definition, Regulatory Boundaries and Specification. Pubrica. https://pubrica.com/academy/concepts-definitions/what-is-an-active-pharmaceutical-ingredient/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

API description block for a methods section

This block should be completed before the paragraph is drafted. Each completed line becomes one clause; each blank line is a question a reviewer can ask. For a biologic or an advanced therapy, the alternative block at the end should be used instead.

ACTIVE SUBSTANCE DESCRIPTION BLOCK

1. IDENTITY
   Compound (INN or chemical name) .... ______________________________
   Salt / free form ................... [ ] free acid  [ ] free base
                                        [ ] salt, counter-ion: ____________
   Dose basis used in this paper ...... [ ] salt  [ ] free base
                                        conversion factor: ____________
   Confirmed by ....................... [ ] NMR  [ ] MS  [ ] IR
                                        [ ] comparison with reference standard
   Reference standard ................. [ ] compendial  [ ] in-house (characterisation attached)

2. SOLID FORM
   Form ............................... [ ] anhydrous, polymorph ______
                                        [ ] hydrate, stoichiometry ______
                                        [ ] solvate  [ ] co-crystal  [ ] amorphous
   Confirmed by ....................... [ ] XRPD  [ ] DSC  [ ] TGA
                                        [ ] ssNMR  [ ] Raman
   Re-checked after storage? .......... [ ] yes, at ____ months  [ ] no
   Water content (method) ............. __________  (  ) Karl Fischer  (  ) TGA
   Hygroscopicity (DVS) ............... __________

3. PARTICLE SIZE  (state even when not critical; say so if not)
   Method ............................. ______________________________
   Dispersion medium / method ......... ______________________________
   d10 ______  d50 ______  d90 ______   Span ______

4. SOURCE
   [ ] Purchased  Supplier ____________  Lot ____________  Stated assay ______
   [ ] Synthesised in-house
       Declared starting material ..... ______________________________
       Route (steps) .................. ______________________________
       Purification ................... ______________________________
   Number of lots used in this study .. ______  (one lot throughout? Y / N)
   Storage conditions ................. ______________________________

5. SPECIFICATION  (criteria, not results)
   Assay .............................. ______ to ______ %, basis: ____________
   Largest individual impurity ........ not more than ______ %
   Total impurities ................... not more than ______ %
   Reporting threshold ................ ______ %   Identification threshold ______ %
   Residual solvents (class / limit) .. ______________________________
   Elemental impurities ............... ______________________________
   Microbiological quality ............ ______________________________

6. ANALYTICAL METHOD
   Technique and detection ............ ______________________________
   Validated range .................... ______ to ______
   Stability-indicating demonstrated .. [ ] yes, forced degradation data in ______
                                        [ ] no  (then do not claim it)

ALTERNATIVE BLOCK: BIOLOGIC / ADVANCED THERAPY
   Active principle described as ...... [ ] protein / mAb  [ ] nucleic acid
                                        [ ] vector + transgene  [ ] cell product
   Expression or production system .... ______________________________
   Higher-order structure method ...... ______________________________
   Heterogeneity characterised ........ [ ] charge  [ ] size  [ ] glycosylation
   Aggregation method and result ...... ______________________________
   Potency assay (what it measures) ... ______________________________
   Process steps treated as part of the product definition: ______________

Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.

How Pubrica can help

Pubrica’s regulatory writing and medical writing teams convert batch records, certificates of analysis and characterisation data into drug substance sections that state criteria rather than results — identity, salt, solid form, impurity limits, particle size and method validation in the order a reviewer reads them. Where the work is on a biologic or an advanced therapy, Pubrica assists in selecting vocabulary and critical quality attributes that fit the product instead of forcing a small-molecule frame onto it.

Find something else

Search the Pubrica Academy

Access is free and requires no account. Enter a topic, or open the full library to filter by category, sub-topic or resource type.

Pubrica reviews drug substance sections and certificates of analysis and identifies the claims that the manuscript does not yet support.

A scoping assessment is free and takes two business days. It provides a written assessment of what the work requires and which specialist would undertake it.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.